• Diagnosed with MCL (mantle cell lymphoma) through flow cytometry or histopathology, and has not received prior treatment.

• Age \> 18 years of age, both genders are eligible.

• Ann Arbor stage II-IV; for stage II subjects, those who require systemic therapy based on the investigator's judgment are eligible.

• At least one measurable lesion.

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.

• Any one of the following high-risk factors is present: MIPI score of 4-11, Ki67 \> 50%, TP53 abnormality, blastic or pleomorphic variation.

• Patients who are not suitable candidates for autologous hematopoietic stem cell transplantation.

• Laboratory tests (blood routine, liver and kidney function) meet the following requirements: a) Blood routine: White blood cell count ≥3.0×10\^9/L, absolute neutrophil count ≥1.5×10\^9/L, hemoglobin ≥90g/L, platelet count ≥75×10\^9/L. b) Liver function: Transaminases ≤2.5 times the upper limit of normal, bilirubin ≤1.5 times the upper limit of normal. c) Serum creatinine 44-133 mmol/L.

• The investigator judges that the subject's life expectancy is greater than 12 weeks from the time of screening.

• Willing and able to participate in all required assessments and procedures of the study protocol.